Joanna Robson1, Helen Doll2, Ravi Suppiah2, Oliver Flossmann2, Lorraine Harper2, Peter Höglund2, David Jayne2, Alfred Mahr2, Kerstin Westman2, Raashid Luqmani2. 1. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science (NDORMs), University of Oxford, Rheumatology Department, Nuffield Orthopaedic Centre, Oxford, Department of Population Health, Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK, Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, Renal Department, Royal Berkshire NHS Foundation Trust, Reading, Centre for Translational Inflammation Research, School of Immunity and Infection, University of Birmingham, Birmingham, UK, Competence Centre for Clinical Research, Skane University Hospital, Lund, Sweden, Renal Department, Addenbrooke's Hospital, Cambridge, UK, Department of Internal Medicine, Hospital Saint-Louis, Paris, France and Nephrology and Transplantation, Skane University Hospital Malmo, Lund University, Malmo, Sweden. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science (NDORMs), University of Oxford, Rheumatology Department, Nuffield Orthopaedic Centre, Oxford, Department of Population Health, Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK, Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, Renal Department, Royal Berkshire NHS Foundation Trust, Reading, Centre for Translational Inflammation Research, School of Immunity and Infection, University of Birmingham, Birmingham, UK, Competence Centre for Clinical Research, Skane University Hospital, Lund, Sweden, Renal Department, Addenbrooke's Hospital, Cambridge, UK, Department of Internal Medicine, Hospital Saint-Louis, Paris, France and Nephrology and Transplantation, Skane University Hospital Malmo, Lund University, Malmo, Sweden. joanna.robson@ndorms.ox.ac.uk. 2. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science (NDORMs), University of Oxford, Rheumatology Department, Nuffield Orthopaedic Centre, Oxford, Department of Population Health, Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK, Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, Renal Department, Royal Berkshire NHS Foundation Trust, Reading, Centre for Translational Inflammation Research, School of Immunity and Infection, University of Birmingham, Birmingham, UK, Competence Centre for Clinical Research, Skane University Hospital, Lund, Sweden, Renal Department, Addenbrooke's Hospital, Cambridge, UK, Department of Internal Medicine, Hospital Saint-Louis, Paris, France and Nephrology and Transplantation, Skane University Hospital Malmo, Lund University, Malmo, Sweden.
Abstract
OBJECTIVE: Granulomatosis with polyangiitis and microscopic polyangiitis are ANCA-associated vasculitides (AAVs). The Vasculitis Damage Index (VDI) quantifies damage. This study aims to determine the factors associated with long-term damage in the AAVs. METHODS: Data from 535 patients from four European Vasculitis Study Group trials were studied. A long-term follow-up (LTFU) questionnaire at 7 years post-diagnosis was completed. The associations between baseline (age, creatinine and BVAS score) and cumulative (number of relapses and duration of glucocorticoid use) factors and damage accrued (total VDI scores and individual treatment-related damage items) during follow-up were explored. Multiple regressions identified independent associations between baseline measures, cumulative factors and VDI scores at LTFU. RESULTS: Two hundred and ninety-six patients had glucocorticoid use and VDI data available at LTFU, with the mean length of glucocorticoid use being 40.4 months (S.D. 16.7). High levels of damage were independently associated with older age at baseline (P = 0.051), lower glomerular filtration rate (P = 0.041), higher BVAS scores (P = 0.046), increased cumulative glucocorticoid use (P = 0.016) and increasing number of relapses. Patients with longer duration of glucocorticoid treatment were more likely to have a total VDI score ≥5 [odds ratio 1.26 per 12 months of glucocorticoid use (95% CI 1.03, 1.53), P = 0.022]. The main limitation is that approximately half of the patients enrolled had no LTFU data available; these patients were older with more severe initial disease. CONCLUSION: Long-term damage in the AAVs may be associated with severity of initial disease, age, number of relapses and duration of glucocorticoid use.
OBJECTIVE:Granulomatosis with polyangiitis and microscopic polyangiitis are ANCA-associated vasculitides (AAVs). The Vasculitis Damage Index (VDI) quantifies damage. This study aims to determine the factors associated with long-term damage in the AAVs. METHODS: Data from 535 patients from four European Vasculitis Study Group trials were studied. A long-term follow-up (LTFU) questionnaire at 7 years post-diagnosis was completed. The associations between baseline (age, creatinine and BVAS score) and cumulative (number of relapses and duration of glucocorticoid use) factors and damage accrued (total VDI scores and individual treatment-related damage items) during follow-up were explored. Multiple regressions identified independent associations between baseline measures, cumulative factors and VDI scores at LTFU. RESULTS: Two hundred and ninety-six patients had glucocorticoid use and VDI data available at LTFU, with the mean length of glucocorticoid use being 40.4 months (S.D. 16.7). High levels of damage were independently associated with older age at baseline (P = 0.051), lower glomerular filtration rate (P = 0.041), higher BVAS scores (P = 0.046), increased cumulative glucocorticoid use (P = 0.016) and increasing number of relapses. Patients with longer duration of glucocorticoid treatment were more likely to have a total VDI score ≥5 [odds ratio 1.26 per 12 months of glucocorticoid use (95% CI 1.03, 1.53), P = 0.022]. The main limitation is that approximately half of the patients enrolled had no LTFU data available; these patients were older with more severe initial disease. CONCLUSION: Long-term damage in the AAVs may be associated with severity of initial disease, age, number of relapses and duration of glucocorticoid use.
Authors: Tariq E Farrah; Maria Prendecki; Robert W Hunter; Rashmi Lahiri; Thomas D Cairns; Charles D Pusey; Stephen P McAdoo; Neeraj Dhaun Journal: Nephrol Dial Transplant Date: 2021-03-29 Impact factor: 5.992
Authors: David R W Jayne; Annette N Bruchfeld; Lorraine Harper; Matthias Schaier; Michael C Venning; Patrick Hamilton; Volker Burst; Franziska Grundmann; Michel Jadoul; István Szombati; Vladimír Tesař; Mårten Segelmark; Antonia Potarca; Thomas J Schall; Pirow Bekker Journal: J Am Soc Nephrol Date: 2017-04-11 Impact factor: 10.121
Authors: Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig Journal: Z Rheumatol Date: 2017-11 Impact factor: 1.372
Authors: Tanaz A Kermani; Antoine G Sreih; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Paul A Monach; Larry Moreland; Christian Pagnoux; Philip Seo; Kenneth J Warrington; Steven R Ytterberg; Peter A Merkel Journal: Rheumatology (Oxford) Date: 2018-02-01 Impact factor: 7.580
Authors: Joanna C Robson; Jill Dawson; Helen Doll; Peter F Cronholm; Nataliya Milman; Katherine Kellom; Susan Ashdown; Ebony Easley; Don Gebhart; Georgia Lanier; John Mills; Jacqueline Peck; Raashid Ahmed Luqmani; Judy Shea; Gunnar Tomasson; Peter A Merkel Journal: Ann Rheum Dis Date: 2018-04-25 Impact factor: 19.103
Authors: Adam D Morris; Camilo L M Morais; Kássio M G Lima; Daniel L D Freitas; Mark E Brady; Ajay P Dhaygude; Anthony W Rowbottom; Francis L Martin Journal: Sci Rep Date: 2021-05-11 Impact factor: 4.379